Nest Genomics

Nest Genomics develops a software platform that integrates genetic testing information into electronic medical records (EMRs), enabling healthcare providers to inform treatment decisions with data-driven insights. The platform, launched in the last quarter of 2022, automatically generates personalized care plans for patients based on their genetic test results. For instance, a patient at risk for breast cancer would receive a plan including imaging, referrals to specialists, and recommendations for preventive medication.

The company's initial focus is on cardiology and oncology, where genetic testing is already utilized to assess and treat patients at risk for heart disease or cancer. Nest Genomics' platform seamlessly integrates with existing EMR systems, facilitating provider care decisions and helping patients schedule follow-up appointments.

In 2020, the American Heart Association recommended genetic testing to diagnose patients with a family history of heart disease, while the National Cancer Institute advocates genetic counseling and testing for at-risk patients and those with a hereditary cancer risk.

Nest Genomics was co-founded in 2022 by Moran Snir and Guy Snir, a married couple who previously co-founded Clear Genetics, a developer of software for providing genetic services to patients, which was acquired by Invitae Corp in 2019.